Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vera Therapeutics, Inc. (Nasdaq: VERA) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a late clinical-stage biotechnology company focused on serious immunological diseases, Vera Therapeutics uses SEC filings to report clinical milestones, financing transactions, governance changes, and other material events that can be important for investors analyzing VERA stock.
Current reports on Form 8-K feature prominently in Vera Therapeutics’ filing history. For example, the company has filed 8-Ks describing entry into a Sales Agreement with TD Securities (USA) LLC for potential at-the-market offerings of Class A common stock, the pricing of underwritten public offerings of Class A common stock, and the termination of a prior sales agreement. Other 8-Ks report clinical and regulatory updates, such as ORIGIN Phase 3 trial data for atacicept in immunoglobulin A nephropathy (IgAN), including reductions in proteinuria and safety outcomes, as well as the submission of a Biologics License Application and subsequent communications around FDA review.
Filings also cover corporate governance and compensation. Vera Therapeutics has reported the appointment of new directors, including committee assignments and equity compensation under its non-employee director compensation policy, and changes in executive roles such as the departure of its Chief Legal Officer. Additional disclosures describe inducement equity awards granted under the company’s 2024 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
Alongside 8-Ks, investors can access registration statements and prospectus supplements referenced in the filings, which relate to public offerings and shelf registration on Form S-3. These documents outline the terms under which Vera Therapeutics may issue Class A common stock to fund its development programs, including atacicept, VT-109, and MAU868.
On Stock Titan, Vera Therapeutics’ SEC filings are updated in near real time from EDGAR. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as clinical trial disclosures, financing capacity, director and officer changes, and at-the-market sales arrangements. Users can quickly scan which filings relate to clinical data, capital raising, or governance, and then drill down into the full text when more detail is needed.
For those tracking insider and equity-related activity, the filings page complements Forms 4 and other ownership reports by surfacing information on option grants, RSUs, and inducement awards described in 8-Ks. Together, these materials provide a detailed view of how Vera Therapeutics structures incentives and finances its late-stage development efforts in immunology and nephrology.
Vera Therapeutics, Inc. President and CEO Marshall Fordyce reported open‑market sales of Class A Common Stock on April 14, 2026. He sold 14,130 shares at an average price of $43.6649, 7,921 shares at $44.5784, and 900 shares at $45.5114, totaling 22,951 shares sold.
These transactions were executed pursuant to a pre‑arranged Rule 10b5‑1(c) trading plan adopted on January 9, 2026. Following the sales, Fordyce directly holds 235,244 shares. He also has indirect holdings of 122,949 shares through a GRAT and 99,081 shares through a trust, which together include 1,032 shares acquired under the company’s 2021 Employee Stock Purchase Plan on March 13, 2026.
VERA reported a Form 144 notice showing a sale of 16,925 shares of Common Stock by Marshall Fordyce on 02/23/2026 for $710,577.51. The filing also lists 22,951 Restricted Stock Units dated 02/20/2026 as securities to be sold.
The sale is recorded on a Form 144 for Nasdaq-listed shares; the filing lists Morgan Stanley Smith Barney LLC as a broker/dealer contact. No additional proceeds treatment or holder limits are stated in the excerpt.
Vera Therapeutics, Inc. has called its 2026 Annual Meeting of Stockholders for May 21, 2026, to be held exclusively online via webcast. Holders of Class A common stock at the March 24, 2026 record date, when 71,713,905 shares were outstanding, may vote.
Stockholders will vote on electing three Class II directors to terms ending at the 2029 meeting, ratifying KPMG LLP as independent auditor for 2026, and approving an advisory "say‑on‑pay" resolution on executive compensation. The board recommends voting for all three proposals.
The proxy describes Vera’s classified 11‑member board, committee structure, and independence determinations, and details executive pay practices emphasizing performance‑based annual bonuses and multi‑year equity awards. It also outlines stock ownership of significant investors and insiders, governance policies (including a clawback and insider trading policy), and procedures for submitting future stockholder proposals and director nominations.
Vera Therapeutics, Inc. was reported as having 1,229,525 shares of Class A Common Stock beneficially owned by Point72-affiliated filers, representing 1.7% of the class as of March 31, 2026. The reported holdings include 17,800 shares issuable upon exercise of call options held by the managed fund. The filing is a joint Schedule 13G by Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen and states that the reporting persons have shared voting and dispositive power over the 1,229,525 shares.
Vera Therapeutics Inc ownership disclosure: The Vanguard Group amended its Schedule 13G to report 0 shares beneficially owned of Vera Therapeutics common stock, representing 0% of the class, following an internal realignment.
The filing states that on January 12, 2026 Vanguard reorganized and certain subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The amendment is signed by Ashley Grim on 03/27/2026.
Vera Therapeutics Chief Legal Officer Jane Wright-Mitchell received new equity awards. She was granted a stock option for 56,850 shares of Class A Common Stock at an exercise price of $40.73 per share, expiring on March 22, 2036.
She also received 42,403 restricted stock units under the 2024 Inducement Plan, representing 42,403 shares of Class A Common Stock. According to the vesting terms, one-fourth of the RSUs vest on each of May 20, 2027, 2028, 2029 and 2030, while the option vests 12/48ths on March 23, 2027 and 1/48th monthly thereafter, in each case contingent on continued service.
Vera Therapeutics, Inc. filed an initial insider ownership report for Chief Legal Officer Jane Wright-Mitchell. This Form 3 establishes her status as an officer subject to insider reporting rules. The structured data provided shows no insider share transactions or derivative holdings reported in this filing.
Vera Therapeutics, Inc. senior vice president of finance and chief accounting officer Joseph R. Young exercised stock options to acquire 10,000 shares of Class A common stock at an exercise price of $3.9396 per share on March 13, 2026.
Following the transactions, he directly owns 75,754 shares of Class A common stock and holds 38,589 stock options. The filing notes that 1,032 of his shares were acquired through the company’s 2021 Employee Stock Purchase Plan, and the option grant vests over time, with a portion vesting monthly.
Vera Therapeutics reports a Schedule 13G filing showing Deep Track-affiliated holders beneficially own 3,921,362 shares of Class A common stock. That holding represents 5.50% of the class based on 71,355,667 shares outstanding as of February 23, 2026.
The filing lists Deep Track Capital, LP and Deep Track Biotechnology Master Fund, Ltd., with shared voting and dispositive power over the 3,921,362 shares, and identifies David Kroin as a control person for the Deep Track entities.